Set, Ready, Afford: China Rushes To Access Innovation Amid New Drug Dash
Executive Summary
2018 is set to break the record for new drug approvals in China, which have included some immuno-oncology and powerful antiviral therapies. Providing access to these high-priced medicines to more patients in the populous country was high on the minds of several multinationals during a recent conference in Shanghai.
You may also be interested in...
Eight For 8: Things You Need To Know About China Biopharma Commercial In 2018
From AI to IPOs, from access models to mobile payments, China’s biopharma sector increasingly became a global leader in biotech financing and digital health innovation in 2018. Here is Scrip's pick of eight key events that captured the major developments in China’s dynamic, highly fluid biopharma commercial scene throughout the year.
Invitation Extended: New Chinese Policies Aim To Lure Foreign Pharma Firms
In their latest charm offensive, Chinese regulators issue policies clearly designed to encourage the import of innovative drugs from overseas and better serve foreign drug makers already operating in the country.
China Relaxes Restrictions Amid 'Zero' Severe Shanghai Cases
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.